Pulmonx’s (LUNG) “Buy” Rating Reaffirmed at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Pulmonx (NASDAQ:LUNG) in a research report sent to investors on Friday morning,Benzinga reports. The brokerage currently has a $14.00 price target on the stock.

Several other equities analysts have also commented on the stock. Wall Street Zen upgraded shares of Pulmonx from a “sell” rating to a “hold” rating in a research report on Sunday, November 16th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Pulmonx in a research report on Thursday, January 22nd. Finally, Lake Street Capital decreased their target price on shares of Pulmonx from $8.00 to $4.00 and set a “buy” rating for the company in a research report on Tuesday, October 28th. Five research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $6.81.

Pulmonx Trading Up 6.0%

Shares of NASDAQ LUNG opened at $1.51 on Friday. Pulmonx has a 12-month low of $1.31 and a 12-month high of $9.35. The company has a market cap of $62.08 million, a price-to-earnings ratio of -1.07 and a beta of 0.07. The company has a current ratio of 4.86, a quick ratio of 4.15 and a debt-to-equity ratio of 0.62. The stock’s 50 day simple moving average is $1.92 and its 200 day simple moving average is $1.79.

Hedge Funds Weigh In On Pulmonx

A number of institutional investors and hedge funds have recently bought and sold shares of LUNG. Corton Capital Inc. bought a new stake in shares of Pulmonx during the 2nd quarter worth about $32,000. Cerity Partners LLC bought a new position in shares of Pulmonx in the fourth quarter valued at approximately $27,000. Opal Capital LLC acquired a new position in shares of Pulmonx during the fourth quarter valued at approximately $29,000. Regatta Capital Group LLC bought a new stake in Pulmonx during the fourth quarter worth approximately $30,000. Finally, Lazard Asset Management LLC bought a new stake in Pulmonx during the fourth quarter worth approximately $31,000. Institutional investors own 91.04% of the company’s stock.

About Pulmonx

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.